We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Effect of Vitamin D Repletion on Small Low Density Lipoprotein (LDL) Particle Number in Subjects at Elevated Cardiovascular Risk

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: November 5, 2009
Last Update Posted: June 1, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Rockefeller University
Vitamin D is a fat-soluble vitamin that is naturally present in very few foods, added to others, and available as a dietary supplement. It is also produced in the body when ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis. Vitamin D is essential for promoting calcium absorption and maintaining adequate serum calcium and phosphate concentrations to enable normal mineralization of bone and bone growth. Without sufficient vitamin D, bones can become thin, brittle, or misshapen. Vitamin D sufficiency prevents rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis. Many people have low levels of Vitamin D. Replacing Vitamin D is thought to help lower the risk of heart disease. Vitamin D may be helpful, but it could also be harmful. The investigators are studying the effect of Vitamin D on the level of a harmful kind of cholesterol. Participants will have their cholesterol levels measured and then receive either Vitamin D or a placebo. After 2 months of treatment, the investigators will measure their cholesterol levels again.

Condition Intervention
Atherosclerosis Dietary Supplement: Vitamin D3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Official Title: The Effect of Vitamin D Repletion on Small LDL Particle Number in Subjects at Elevated Cardiovascular Risk

Resource links provided by NLM:

Further study details as provided by Rockefeller University:

Primary Outcome Measures:
  • Small LDL particle concentration [ Time Frame: Visit 5 ]

Enrollment: 150
Study Start Date: October 2009
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: placebo
Experimental: Vitamin D3
Vitamin D3 given for 8 weeks
Dietary Supplement: Vitamin D3
50,000 units taken orally once a week for 8 weeks


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age > 18 years and < 85 years
  2. Vitamin D 25-OH level <20 ng/ml
  3. One of the following risk factors:

    • Known coronary artery disease (CAD) or a CAD equivalent (e.g. diabetes, chronic kidney disease, etc)
    • BMI > 30 kg/m2
    • Random Glucose Level > 200mg/dl
    • Increased Waist Circumference (male: > 40in; Females: > 35in.)
    • Decreased HDL (Male: < 40mg/dl; Female: < 50mf/dl)
    • Framingham Risk Score > 10%
    • hsCRP > 2 mg/L

Exclusion Criteria:

  1. Serum phosphorus level > 5.5 mg/dl
  2. Estimated GFR <30 ml/min/1.73m2
  3. Use of Vitamin D >400 IU/day within 1 month of most recent Vitamin D 25-OH determination
  4. Use of calcitriol or other "activated" vitamin D
  5. Change in statin, ezetimibe, niacin, fibrate dose within 1 month
  6. Concurrent participation in an investigational drug study
  7. Have any other condition, which in the opinion of the investigator, should prohibit the participation in the study
  8. Serum calcium level >10.5 mg/dl
  9. anti-epileptic medication
  10. triglycerides > 400 mg/dL
  11. BMI > 40 kg/m2
  12. Evidence of cirrhosis as evidenced by AST > 3 x upper limit, ALT > 3 x upper limit, bilirubin > 1.5 mg/dL , albumin < 3.0 g/dL, PT > 14.5 sec
  13. Pregnant or Lactating Females
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01008384

United States, New York
The Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
Rockefeller University
Principal Investigator: Manish Ponda, MD The Rockefeller University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Rockefeller University
ClinicalTrials.gov Identifier: NCT01008384     History of Changes
Other Study ID Numbers: MAP-0683
First Submitted: October 22, 2009
First Posted: November 5, 2009
Last Update Posted: June 1, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents